•LSE:IMMadvanced approximately7.74%during trading on21 July 2026, emerging among the strongest-performing UK healthcare shares.
Companies in the healthcare & biotech space are typically valued using metrics relevant to their business model and sector peers.
Companies in the healthcare & diagnostics space are typically valued using metrics relevant to their business model and sector peers.
MedPal AI plc (LSE:MPAL) is a London-based digital health company that joined the AIM market of the London Stock Exchange in August 2025. Its founding proposition was consumer-first and deliberately non-clinical: a smartphone application that aggregates and monitors a user's health metrics and offers …
Sareum Holdings plc (LSE:SAR) is a United Kingdom drug discovery company quoted on London's AIM market and based in Cambridge. It specialises in small-molecule kinase inhibitors, an area of drug design targeting the enzymes that drive many diseases, and has built its pipeline around …
Avacta Group (LSE:AVCT) is a British clinical-stage biotechnology company that has spent the past eighteen months transforming from a diversified life-sciences group into a focused precision-oncology developer. Historically the business combined a therapeutics arm with a profitable diagnostics division, but management concluded the two …
ImmuPharma Plc, listed on London's AIM market under the ticker IMM, is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics, with a long-standing focus on autoimmune disease. Its defining asset is P140, a synthetic peptide historically branded Lupuzor and described as a …
ECO Animal Health Group plc is a London-headquartered developer and marketer of medicines for farmed animals, quoted on London's AIM market under the ticker EAH. Its business has historically centred on Aivlosin, a macrolide antibiotic based on the active ingredient tylvalosin, used to treat …
Sareum Holdings plc (LSE:SAR) is a small UK drug-discovery company developing selective kinase inhibitors for autoimmune, inflammatory and cancer indications. Its lead asset is SDC-1801, an oral small molecule designed to inhibit two enzymes, tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1). These …
As of 21 July 2026, Bioventix PLC (LSE:BVXP) shares were down2.58%, making the biotechnology company one of the notable decliners on the London market today. Despite the weakness, there wasno material company-specific regulatory announcementreleased during the trading session that directly explained the decline. The …